Total Funding
87
76
Total FundingVenture - Series Unknown raised
Growth Score
-10 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
20226
Aminex Therapeutics develops small molecule based cancer treatment solutions.
Thomas Graham: Chief Operating Officer
Mark Burns: President & CEOPast Role: MediQuest Therapeutics, Executive Director of Chemistry
About the Company
Aminex Therapeutics, Inc. is a drug development company focused on the discovery, development, and commercialization of suppressor cell modulators (SCM), a new class of small molecule cancer immunotherapies that enable the immune system to attack cancer by regulating myeloid-derived suppressor cells. Aminex has extensively demonstrated, in animal
trials, the potential of its lead drug, AMX-513, to be effective alone and to improve overall therapy when used in combination with other cancer treatments. Aminex's vision is to make significant treatment contributions for a wide range of cancers and to ease the rising costs of cancer therapy.
